Literature DB >> 16359827

The dialectics of cancer: A theory of the initiation and development of cancer through errors in RNAi.

Coral V A Wynter1.   

Abstract

The recent discoveries of the RNA-mediated interference system in cells could explain all of the known features of human carcinogenesis. A key, novel idea, proposed here, is that the cell has the ability to recognise a mutated protein and/or mRNA. Secondly, the cell can generate its own short interfering RNA (siRNA) using an RNA polymerase to destroy mutated mRNA, even when only a single base pair in the gene has mutated. The anti-sense strand of the short RNA molecule (called sicRNA), targets the mutated mRNA of an oncogene or a tumour suppressor. The resulting double stranded RNA, using the RNA-induced silencing complex in the cytoplasm dices the mutated mRNA. In cancer-prone tissues, during cell mitosis, the sicRNA complex can move into the nucleus to target the mutated gene. The sicRNA, possibly edited by dsRNA-specific adenosine deaminase, converting adenosines to inosines, can be retained in the nucleus, with enhanced destructive capability. The sicRNA triggers the assembly of protein complexes leading to epigenetic modification of the promoter site of the mutant gene, specifically methylation of cytosines. In some instances, instead of methylation, the homologous DNA is degraded, leading to loss of heterozygosity. The factors controlling these two actions are unknown but the result is gene silencing or physical destruction of the mutant gene. The cell survives dependent on the functioning of the single, wild-type allele. An error in RNAi defence occurs when the sicRNA enters the nucleus and targets the sense strand of the wrong DNA. The sicRNA, because of the similarity of its short sequence and relaxed stringency, can target other RNAs, which are being transcribed. This can result in the methylation of the wrong promoter site of a gene or LOH of that region. In the vast majority of these cases, the aberrant hybridisations will have no effect on cell function or apoptosis eliminates non-viable cells. On a rare occasion, a preneoplastic cell is initiated when aberrant hybridisations switches on/off a gene involved in apoptosis, as well as a gene involved in cell proliferation and DNA damage surveillance. Genetic instability results when the sicRNA competes for a repeat sequence in the centromere or telomere, leading to gross chromosomal rearrangements. A malignancy develops when the sicRNAs fortuitously targets a microRNA (miRNA) or activates a transcription factor, resulting in the translation of a large number of new genes, alien to that tissue. This leads to dedifferentiation of the tissue, a resculpting of the histone code, chromosomal rearrangements, along a number of specific pathways, the gain of immortality and the dissemination of a metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16359827     DOI: 10.1016/j.mehy.2005.10.024

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

1.  High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells.

Authors:  Carl Christoph Schimanski; Kirsten Frerichs; Fareed Rahman; Martin Berger; Hauke Lang; Peter R Galle; Markus Moehler; Ines Gockel
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

Review 2.  Encapsulation of nucleic acids and opportunities for cancer treatment.

Authors:  Lisa Brannon-Peppas; Bilal Ghosn; Krishnendu Roy; Kenneth Cornetta
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

3.  MiRNA-mRNA crosstalk in laryngeal squamous cell carcinoma based on the TCGA database.

Authors:  Guan-Jiang Huang; Meng-Si Luo; Guo-Ping Chen; Min-Yi Fu
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-01-13       Impact factor: 2.503

4.  MicroRNA expression profile in head and neck cancer: HOX-cluster embedded microRNA-196a and microRNA-10b dysregulation implicated in cell proliferation.

Authors:  Patricia Severino; Holger Brüggemann; Flavia Maziero Andreghetto; Carme Camps; Maria de Fatima Garrido Klingbeil; Welbert Oliveira de Pereira; Renata Machado Soares; Raquel Moyses; Victor Wünsch-Filho; Monica Beatriz Mathor; Fabio Daumas Nunes; Jiannis Ragoussis; Eloiza Helena Tajara
Journal:  BMC Cancer       Date:  2013-11-09       Impact factor: 4.430

5.  MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1.

Authors:  L Shi; B Zhang; X Sun; S Lu; Z Liu; Y Liu; H Li; L Wang; X Wang; C Zhao
Journal:  Br J Cancer       Date:  2014-11-20       Impact factor: 7.640

6.  Different effects of three polymorphisms in MicroRNAs on cancer risk in Asian population: evidence from published literatures.

Authors:  Yeqiong Xu; Ling Gu; Yuqin Pan; Rui Li; Tianyi Gao; Guoqi Song; Zhenlin Nie; Liping Chen; Shukui Wang; Bangshun He
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

7.  MicroRNA-196a is a putative diagnostic biomarker and therapeutic target for laryngeal cancer.

Authors:  Koichiro Saito; Koji Inagaki; Takahiro Kamimoto; Yoko Ito; Toshiaki Sugita; Satoko Nakajo; Akira Hirasawa; Arifumi Iwamaru; Takashi Ishikura; Hideki Hanaoka; Keisuke Okubo; Tokio Onozaki; Takeru Zama
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.